Fibromyalgia Treatment Market size was USD 3.23 Billion in 2023 and is expected to Reach USD 4.52 Billion by 2031 and grow at a CAGR of 4.3 % over the forecast period of 2024-2031.
Fibromyalgia treatment focuses on managing the symptoms and improving the quality of life for individuals with the condition. Medications may be provided to assist control the symptoms of fibromyalgia. Commonly used medications include pain relievers such as acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and prescription drugs like tramadol. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), can also be prescribed to help alleviate pain and improve sleep. Physical therapy aims to improve muscle strength, flexibility, and overall physical function. It often involves a combination of exercises, stretching, and low-impact aerobic conditioning. Physical therapists may also use techniques like massage therapy, heat therapy, or ultrasound therapy to help reduce pain.
CBT is a type of talk therapy that focuses on addressing the emotional and psychological aspects of fibromyalgia. It helps someone develop and manage stress, coping strategies and improve their overall goodness. CBT can be beneficial in reducing pain perception, improving sleep, and enhancing daily functioning. Making certain lifestyle changes can help manage fibromyalgia symptoms. This may include adopting a regular sleep schedule, practising stress management techniques (such as meditation or relaxation exercises), engaging in low-impact exercises like swimming or walking, and maintaining a healthy diet. Some individuals find relief from fibromyalgia symptoms through complementary therapies, although the scientific evidence supporting their effectiveness is limited. These may include acupuncture, massage therapy, chiropractic care, herbal supplements, or mind-body techniques like yoga or tai chi. It's important to consult with a healthcare professional before trying any complementary therapy.
A key commercial difficulty in developing nations is a lack of information about the situation. Lack of awareness is exacerbated by limited healthcare resources and poor education on fibromyalgia among healthcare providers and the general community. In these locations, a lack of knowledge hinders early identification, diagnosis, and adequate management of fibromyalgia, resulting in a negative influence on the growth of the fibromyalgia treatment market share. On the contrary, academics and pharmaceutical firms continue to investigate and develop novel fibromyalgia therapy alternatives. These include drugs that particularly address the condition's symptoms and underlying processes. Thus, the development of innovative medicines gives additional treatment alternatives for healthcare professionals and patients, which is expected to boost the market throughout the projected period for the fibromyalgia treatment market.
DRIVERS:
Established industry leaders are actively launching novel fibromyalgia therapies in order to build or maintain their market position.
The rising prevalence of fibromyalgia is expected to drive market expansion.
The worldwide fibromyalgia treatment market is being driven by a number of factors. The major factor that is expected to boost the market is the worldwide growth in fibromyalgia. Fibromyalgia affects around five million persons in the United States aged 18 & over, according to the NIAMS.
RESTRAIN:
Fibromyalgia can be difficult to diagnose due to its subjective nature and the absence of specific diagnostic tests.
Greater adoption of generic drugs & off-label to hindering factors of this market growth.
There are now just three medications that are officially authorized for the treatment of fibromyalgia. This has resulted in the greater use of off-label medications and generic antidepressants to treat the disease's indication. Pfizer also lost the patent protection rights to Lyrica in June 2019. This patent expiry has had a considerable influence on the drug's market revenue. Generic competition is expected to limit market expansion in the coming years.
OPPORTUNITY:
Emerging technologies, such as wearable devices, mobile health applications, and telemedicine, present opportunities for remote monitoring, self-management, and improved access to care for individuals with fibromyalgia.
Patient Education & Empowerment is the most important opportunity in this market.
Increased patient education and empowerment initiatives can help individuals with fibromyalgia better understand their condition, manage their symptoms, and actively participate in their treatment plans. Accessible educational resources, support networks, and self-care tools can empower patients to make informed decisions and improve their quality of life.
CHALLENGES:
Over the projected period, the worldwide fibromyalgia market may be hampered by a shortage of competent professionals who are unable to conduct the therapies.
Side effects allied with the usage of fibromyalgia medications.
Few medicines strengthen the reason for suicidal mind in a few people. Possible adverse effects include nausea, headache, tiredness, high blood pressure, racing heart, excessive perspiration, agitation, a rise in cholesterol and triglycerides, and tremor.
The biotech sectors & pharmaceutical are beginning to be anxious about their ability to keep operations in the rest of the universe. And with good cause. Russia's invasion of Ukraine impacts millions of people worldwide, not only in this Eastern European country. As a result, medication developers will face development delays, a loss of business continuity, and the potential of noncompliance with on-market drugs. Fibromyalgia is a bit of a mystery. It can't be identified with scans or blood tests, yet it causes millions of individuals to suffer for the rest of their lives. The condition primarily affects women (about 76-88% of cases), producing discomfort throughout the body. Because not all healthcare providers are skilled in recognising and diagnosing fibromyalgia, the reported prevalence of the disorder varies widely between countries. It affects just 1% of the population in China, 1.8% in France, 3.5% in Canada, and 9% in Turkey. Estimates in the United States range from 2.2% to 6.4%, whereas in Russia, around 2-3% of the population is afflicted.
Russia is a hub of raw materials related to the pharma sector, after the war between Russia and Ukraine, there has been increased discussion for fibromyalgia treatment worldwide, before the war Russia used to hold a 5% share of raw materials worldwide and due to this war, the demand for raw material in Russia has decreased from 5% to 2.8%.
The COVID-19 pandemic had a huge impact on the healthcare sector, influencing many aspects of patient care, including the management of chronic diseases like fibromyalgia. One of the reasons influencing market expansion was a scarcity of medicines and a disruption in the supply of raw materials utilised to produce the drugs. Furthermore, because of the COVID-19 pandemic, research trials testing novel therapies for fibromyalgia were either paused or postponed.
Furthermore, fibromyalgia syndrome patients, who are already prone to stress-related symptom aggravation, had heightened pain, exhaustion, and other fibromyalgia syndrome symptoms as a result of increased stress and anxiety during the epidemic. This resulted in a rise in demand for fibromyalgia drugs, which boosted the expansion of the fibromyalgia treatment market.
By Drug class
Antidepressants
Anticonvulsants
Muscle relaxants
Others
By Distribution Channel
Hospital Pharmacies
Drug stores
Retail Pharmacies
Online Providers
REGIONAL ANALYSIS
North America: North America held a significant share of the fibromyalgia treatment market in 2023 and is likely to retain its dominance during the forecast period. Several reasons are driving the North American market, including an increase in the prevalence of fibromyalgia, breakthroughs in treatment choices, and a supporting healthcare infrastructure. Furthermore, the presence of a well-established healthcare infrastructure, high purchasing power, and a rise in fibromyalgia medicine acceptability are expected to drive market growth.
Furthermore, the presence of several major players such as Abbvie Inc, Abbott Laboratories, Eli Lilly and Company, Amneal Pharmaceuticals LLC, and Lupin, as well as advancements in manufacturing technologies by these companies to develop efficient products, is driving the fibromyalgia treatment industry in this region.
Asia Pacific: During the projection period, Asia-Pacific is predicted to grow at the quickest rate. Many Asian countries are investing in the improvement of their healthcare facilities. Improved healthcare facilities, easier access to medical personnel, and improvements in healthcare technology all contribute to a favourable environment for fibromyalgia diagnosis and treatment. The expanding healthcare infrastructure contributes to the expansion of the fibromyalgia treatment market.
Furthermore, fibromyalgia awareness is expanding throughout Asia-Pacific. As awareness grows, more people with fibromyalgia symptoms will seek medical treatment and be properly diagnosed. This enhanced awareness and diagnosis lead to market growth.
Some major key players in the Fibromyalgia Treatment Market are Bristol Myers Squibb Company, Pfizer Inc, Janssen Pharmaceuticals, Inc., AstraZeneca, Mylan N.V., Johnson and Johnson Services Inc, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, Sanofi, Merck & Co., Inc, and other players
Amneal Pharmaceuticals, Inc: In 2023, Amneal Pharmaceuticals, Inc. inked a long-term licence arrangement with Orion Corporation to market many of Amneal's complicated generic pharmaceuticals in Europe, Australia, and New Zealand.
AbbVie: In 2020, Following receipt of regulatory approval from all government bodies needed by the purchase agreement, AbbVie finalised its acquisition of Allergan Plc.
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
| Report Attributes | Details |
| Market Size in 2023 | US$ 3.23 Bn |
| Market Size by 2031 | US$ 4.52 Bn |
| CAGR | CAGR of 4.3% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Diagnosis (Blood tests, Others) • By Route of Administration (Parenteral, Oral, Others) • By Treatment (Medication, Therapy, Others) • By End-Users (Specialty Clinics, Homecare, Hospitals, Specialty Clinics, Others) • By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy,) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Bristol Myers Squibb Company, Pfizer Inc, Janssen Pharmaceuticals, Inc., AstraZeneca, Mylan N.V., Johnson and Johnson Services Inc, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, Sanofi, Merck & Co., Inc |
| Key Drivers | • Established industry leaders are actively launching novel fibromyalgia therapies in order to build or maintain their market position. • The rising prevalence of fibromyalgia is expected to drive market expansion. |
| Market Restraints | • Fibromyalgia can be difficult to diagnose due to its subjective nature and the absence of specific diagnostic tests. • Greater adoption of generic drugs & off-label to hindering factors of this market growth. |
Ans: The Fibromyalgia Treatment Market is expected to grow at a CAGR of 4.3%.
Ans: The Fibromyalgia Treatment Market size was USD 3.23 Billion in 2023 and is expected to Reach USD 4.52 Billion by 2031.
Ans: The substantial incidence of fibromyalgia and its awareness among the global population drive the market.
Ans: One of the reasons influencing market expansion was a scarcity of medicines and a disruption in the supply of raw materials utilised to produce the drugs.
Ans: North America held the greatest revenue market share in 2023, accounting for more than two-fifths of the worldwide fibromyalgia treatment market, and is expected to dominate the market over the forecast period.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Impact Analysis
5.1 Impact Of Russia Ukraine Crisis
5.2 Impact of Economic Slowdown on Major Countries
5.2.1 Introduction
5.2.2 United States
5.2.3 Canada
5.2.4 Germany
5.2.5 France
5.2.6 UK
5.2.7 China
5.2.8 Japan
5.2.9 South Korea
5.2.10 India
6. Value Chain Analysis
7. Porter’s 5 Forces Model
8. Pest Analysis
9. Fibromyalgia Treatment Market Segmentation, By Drug Class
Introduction
9.2 Trend Analysis
9.3 Antidepressants
9.4 Anticonvulsants
9.5 Muscle relaxants
Others
10. Fibromyalgia Treatment Market Segmentation, By Distribution channel
Introduction
10.2 Trend Analysis
10.3 Hospital Pharmacies
10.4 Drug stores
10.5 Retail Pharmacies
Online Providers
11. REGIONAL ANALYSIS
11.1 Introduction
11.2 North America
11.2.1 Trend Analysis
11.2.2 North America Fibromyalgia Treatment Market by Country
11.2.3 North America Fibromyalgia Treatment Market By Drug Class
11.2.4 North America Fibromyalgia Treatment Market By Distribution channel
11.2.5 USA
11.2.5.1 USA Fibromyalgia Treatment Market By Drug Class
11.2.5.2 USA Fibromyalgia Treatment Market By Distribution channel
11.2.6 Canada
11.2.6.1 Canada Fibromyalgia Treatment Market By Drug Class
11.2.6.2 Canada Fibromyalgia Treatment Market By Distribution channel
11.2.7 Mexico
11.2.7.1 Mexico Fibromyalgia Treatment Market By Drug Class
11.2.7.2 Mexico Fibromyalgia Treatment Market By Distribution channel
11.3 Europe
11.3.1 Trend Analysis
11.3.2 Eastern Europe
11.3.2.1 Eastern Europe Fibromyalgia Treatment Market by Country
11.3.2.2 Eastern Europe Fibromyalgia Treatment Market By Drug Class
11.3.2.3 Eastern Europe Fibromyalgia Treatment Market By Distribution channel
11.3.2.4 Poland
11.3.2.4.1 Poland Fibromyalgia Treatment Market By Drug Class
11.3.2.4.2 Poland Fibromyalgia Treatment Market By Distribution channel
11.3.2.5 Romania
11.3.2.5.1 Romania Fibromyalgia Treatment Market By Drug Class
11.3.2.5.2 Romania Fibromyalgia Treatment Market By Distribution channel
11.3.2.6 Hungary
11.3.2.6.1 Hungary Fibromyalgia Treatment Market By Drug Class
11.3.2.6.2 Hungary Fibromyalgia Treatment Market By Distribution channel
11.3.2.7 Turkey
11.3.2.7.1 Turkey Fibromyalgia Treatment Market By Drug Class
11.3.2.7.2 Turkey Fibromyalgia Treatment Market By Distribution channel
11.3.2.8 Rest of Eastern Europe
11.3.2.8.1 Rest of Eastern Europe Fibromyalgia Treatment Market By Drug Class
11.3.2.8.2 Rest of Eastern Europe Fibromyalgia Treatment Market By Distribution channel
11.3.3 Western Europe
11.3.3.1 Western Europe Fibromyalgia Treatment Market by Country
11.3.3.2 Western Europe Fibromyalgia Treatment Market By Drug Class
11.3.3.3 Western Europe Fibromyalgia Treatment Market By Distribution channel
11.3.3.4 Germany
11.3.3.4.1 Germany Fibromyalgia Treatment Market By Drug Class
11.3.3.4.2 Germany Fibromyalgia Treatment Market By Distribution channel
11.3.3.5 France
11.3.3.5.1 France Fibromyalgia Treatment Market By Drug Class
11.3.3.5.2 France Fibromyalgia Treatment Market By Distribution channel
11.3.3.6 UK
11.3.3.6.1 UK Fibromyalgia Treatment Market By Drug Class
11.3.3.6.2 UK Fibromyalgia Treatment Market By Distribution channel
11.3.3.7 Italy
11.3.3.7.1 Italy Fibromyalgia Treatment Market By Drug Class
11.3.3.7.2 Italy Fibromyalgia Treatment Market By Distribution channel
11.3.3.8 Spain
11.3.3.8.1 Spain Fibromyalgia Treatment Market By Drug Class
11.3.3.8.2 Spain Fibromyalgia Treatment Market By Distribution channel
11.3.3.9 Netherlands
11.3.3.9.1 Netherlands Fibromyalgia Treatment Market By Drug Class
11.3.3.9.2 Netherlands Fibromyalgia Treatment Market By Distribution channel
11.3.3.10 Switzerland
11.3.3.10.1 Switzerland Fibromyalgia Treatment Market By Drug Class
11.3.3.10.2 Switzerland Fibromyalgia Treatment Market By Distribution channel
11.3.3.11 Austria
11.3.3.11.1 Austria Fibromyalgia Treatment Market By Drug Class
11.3.3.11.2 Austria Fibromyalgia Treatment Market By Distribution channel
11.3.3.12 Rest of Western Europe
11.3.3.12.1 Rest of Western Europe Fibromyalgia Treatment Market By Drug Class
11.3.2.12.2 Rest of Western Europe Fibromyalgia Treatment Market By Distribution channel
11.4 Asia-Pacific
11.4.1 Trend Analysis
11.4.2 Asia Pacific Fibromyalgia Treatment Market by Country
11.4.3 Asia Pacific Fibromyalgia Treatment Market By Drug Class
11.4.4 Asia Pacific Fibromyalgia Treatment Market By Distribution channel
11.4.5 China
11.4.5.1 China Fibromyalgia Treatment Market By Drug Class
11.4.5.2 China Fibromyalgia Treatment Market By Distribution channel
11.4.6 India
11.4.6.1 India Fibromyalgia Treatment Market By Drug Class
11.4.6.2 India Fibromyalgia Treatment Market By Distribution channel
11.4.7 Japan
11.4.7.1 Japan Fibromyalgia Treatment Market By Drug Class
11.4.7.2 Japan Fibromyalgia Treatment Market By Distribution channel
11.4.8 South Korea
11.4.8.1 South Korea Fibromyalgia Treatment Market By Drug Class
11.4.8.2 South Korea Fibromyalgia Treatment Market By Distribution channel
11.4.9 Vietnam
11.4.9.1 Vietnam Fibromyalgia Treatment Market By Drug Class
11.4.9.2 Vietnam Fibromyalgia Treatment Market By Distribution channel
11.4.10 Singapore
11.4.10.1 Singapore Fibromyalgia Treatment Market By Drug Class
11.4.10.2 Singapore Fibromyalgia Treatment Market By Distribution channel
11.4.11 Australia
11.4.11.1 Australia Fibromyalgia Treatment Market By Drug Class
11.4.11.2 Australia Fibromyalgia Treatment Market By Distribution channel
11.4.12 Rest of Asia-Pacific
11.4.12.1 Rest of Asia-Pacific Fibromyalgia Treatment Market By Drug Class
11.4.12.2 Rest of Asia-Pacific Fibromyalgia Treatment Market By Distribution channel
11.5 Middle East & Africa
11.5.1 Trend Analysis
11.5.2 Middle East
11.5.2.1 Middle East Fibromyalgia Treatment Market by Country
11.5.2.2 Middle East Fibromyalgia Treatment Market By Drug Class
11.5.2.3 Middle East Fibromyalgia Treatment Market By Distribution channel
11.5.2.4 UAE
11.5.2.4.1 UAE Fibromyalgia Treatment Market By Drug Class
11.5.2.4.2 UAE Fibromyalgia Treatment Market By Distribution channel
11.5.2.5 Egypt
11.5.2.5.1 Egypt Fibromyalgia Treatment Market By Drug Class
11.5.2.5.2 Egypt Fibromyalgia Treatment Market By Distribution channel
11.5.2.5 South Africa
11.5.2.5.1 South Africa Fibromyalgia Treatment Market By Drug Class
11.5.2.5.2 South Africa Fibromyalgia Treatment Market By Distribution channel
11.5.2.6 Rest of Africa
11.5.2.6.1 Rest of Africa Fibromyalgia Treatment Market By Drug Class
11.5.2.6.2 Rest of Africa Fibromyalgia Treatment Market By Distribution channel
11.5.2.6 Saudi Arabia
11.5.2.6.1 Saudi Arabia Fibromyalgia Treatment Market By Drug Class
11.5.2.6.2 Saudi Arabia Fibromyalgia Treatment Market By Distribution channel
11.5.2.7 Qatar
11.5.2.7.1 Qatar Fibromyalgia Treatment Market By Drug Class
11.5.2.7.2 Qatar Fibromyalgia Treatment Market By Distribution channel
11.5.2.8 Rest of Middle East
11.5.2.8.1 Rest of Middle East Fibromyalgia Treatment Market By Drug Class
11.5.2.8.2 Rest of Middle East Fibromyalgia Treatment Market By Distribution channel
11.5.3 Africa
11.5.3.1 Africa Fibromyalgia Treatment Market by Country
11.5.3.2 Africa Fibromyalgia Treatment Market By Drug Class
11.5.3.3 Africa Fibromyalgia Treatment Market By Distribution channel
11.6 Latin America
11.6.1 Trend Analysis
11.6.2 Latin America Fibromyalgia Treatment Market by Country
11.6.3 Latin America Fibromyalgia Treatment Market By Drug Class
11.6.4 Latin America Fibromyalgia Treatment Market By Distribution channel
11.6.5 Brazil
11.6.5.1 Brazil Fibromyalgia Treatment Market By Drug Class
11.6.5.2 Brazil Fibromyalgia Treatment Market By Distribution channel
11.6.6 Argentina
11.6.6.1 Argentina Fibromyalgia Treatment Market By Drug Class
11.6.6.2 Argentina Fibromyalgia Treatment Market By Distribution channel
11.6.7 Colombia
11.6.7.1 Colombia Fibromyalgia Treatment Market By Drug Class
11.6.7.2 Colombia Fibromyalgia Treatment Market By Distribution channel
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Fibromyalgia Treatment Market By Drug Class
11.6.8.2 Rest of Latin America Fibromyalgia Treatment Market By Distribution channel
12. Company Profiles
12.1 Bristol Myers Squibb Company
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Drug Class s/ Services Offered
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Pfizer Inc
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Drug Class s/ Services Offered
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Janssen Pharmaceuticals, Inc.
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Drug Class s/ Services Offered
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 AstraZeneca
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Drug Class s/ Services Offered
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Mylan N.V.
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Drug Class s/ Services Offered
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Johnson and Johnson Services Inc
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Drug Class s/ Services Offered
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Teva Pharmaceutical Industries Ltd
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Drug Class s/ Services Offered
12.7.4 SWOT Analysis
12.7.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
13.3.1 Industry News
13.3.2 Company News
13.3.3 Mergers & Acquisitions
14. USE Cases and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Speech Therapy Market was valued at USD 10.66 billion in 2023 and is expected to reach at USD 16.38 billion in 2031 and grow at a CAGR of 5.48% over the forecast period of 2024-2031.
In 2022, The Smart Inhalers Market size amounted to USD 13.18 Billion & is estimated to reach USD 53.35 Billion by 2030 and increase at a compound annual growth rate of 19.1% between 2023 and 2030.
The Computer Vision in Healthcare Market Size was valued at USD 1.46 billion in 2023, and is expected to reach USD 33.32 billion by 2031, and grow at a CAGR of 47.8% over the forecast period 2024-2031.
The Cystic Fibrosis Market size was valued at US$ 7.13 Billion in 2022 and is estimated to reach US$ 39.59 Billion by 2030 with a growing CAGR of 23.9% Over the Forecast Period 2023-2030.
The Molecular Modeling Market Size was valued at USD 7.07 billion in 2022 and is expected to reach USD 19.90 billion by 2030 and grow at a CAGR of 13.8% over the forecast period 2023-2030.
The Image-guided Biopsy Market size was valued at USD 2266.21 million in 2022 and is expected to grow to USD 3386.68 million by 2030 and grow at a CAGR of 5.15% over the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
